Symbol="CLLS"
AssetType="Common Stock"
Name="Cellectis SA"
Description="Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France."
CIK="1627281"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, FR"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="102830000"
EBITDA="-71143000"
PERatio="None"
PEGRatio="0"
BookValue="1.737"
DividendPerShare="0"
DividendYield="0"
EPS="-2.18"
RevenuePerShareTTM="0.499"
ProfitMargin="0"
OperatingMarginTTM="-3.198"
ReturnOnAssetsTTM="-0.18"
ReturnOnEquityTTM="-0.629"
RevenueTTM="24759000"
GrossProfitTTM="23952000"
DilutedEPSTTM="-2.18"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.265"
AnalystTargetPrice="6.89"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.479"
PriceToBookRatio="0.75"
EVToRevenue="5.07"
EVToEBITDA="-0.64"
Beta="2.011"
num_52WeekHigh="4.04"
num_52WeekLow="1.68"
num_50DayMovingAverage="2.053"
num_200DayMovingAverage="2.188"
SharesOutstanding="55584000"
DividendDate="None"
ExDividendDate="None"
symbol="CLLS"
open="1.85"
high="1.87"
low="1.84"
price="1.85"
volume="20567.00"
latest_trading_day="2023-08-18"
previous_close="1.87"
change="-0.02"
change_percent="-1.0748%"
aroon_positive_momentum_days="53"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="53"
Volume_recent_avg="60662"
Change_recent_avg="0.01"
Delta_recent_avg="0.11"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-0.25"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="53"
Aroon_momentum_negative="47"
image_negative_thumbnail_id_1="1152"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0185.jpeg"
image_negative_thumbnail_id_2="1100"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0133.jpeg"
image_neutral_thumbnail_id_1="574"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_neutral_thumbnail_id_2="590"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0009.jpeg"
image_positive_thumbnail_id_1="982"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0144.jpeg"
image_positive_thumbnail_id_2="1002"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0164.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1175"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
